Page 138 - Genentech News Today

/PRNewswire/ -- DelveInsights Bispecific Antibody Competitive Landscape – 2023 report provides comprehensive global coverage of available, marketed, and...

The addition of first-line maintenance avelumab to best supportive care has sustained tolerability in patients with advanced urothelial carcinoma.

Margaret DeAngelis runs a lab at the University at Buffalo thats home to a reputable eye bank that holds promising keys to preventing and treating conditions that rob human eyesight.

Dr. Juliana Biondo discusses the exciting FDA approval of Roctavian and how it compares with other treatment options like Hemlibra.

When Lauren Pariani and Kate Schatz first met on a school playground, they had no idea where life would lead them.

Everything2 is a community for fiction, nonfiction, poetry, reviews, and more. Get writing help or enjoy nearly a half million pieces of original writing.

Data from ongoing FIREFISH study confirm long-term efficacy and safety profile of Evrysdi in children with Type 1 SMANinety-one percent of children were...

– Data from ongoing FIREFISH study confirm long-term efficacy and safety profile of Evrysdi in children with Type 1 SMA – – Ninety-one percent of children were alive at month 48 – – More than 95% maintained the ability to swallow - without treatment they would have required feeding support and majority would have died within 2 years – – Evrysdi is now approved in 99 countries with more than 8,500 patients treated globally –

Pembrolizumab led to sustained improvements in recurrence-free survival and distant metastasis-free vs placebo as adjuvant therapy in patients with resected stage IIB or IIC melanoma

I wonder what to write and if Ill want to anymore. One of the things, very hard to do, is to create something when you feel youre using both hands to ...